Equity Overview
Price & Market Data
Price: $26.10
Daily Change: -$0.27 / 1.03%
Daily Range: $25.56 - $27.60
Market Cap: $1,586,121,103
Daily Volume: 181,670
Performance Metrics
1 Week: -6.99%
1 Month: 30.35%
3 Months: -4.12%
6 Months: 868.0%
1 Year: 536.0%
YTD: 7.82%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.